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Abstract
Objective. To investigate the suitability of power Doppler ultrasonography (PD-US) for the assessment of
lymph node (LN) status in RA, evaluating the existence of structural and dynamic modifications in
well-characterized stages of the disease.
Methods. Ten patients with active disease and five patients in clinical remission underwent complete
clinical and PD-US examination of hands, wrists, axillary and cervical LNs on the same day. Synovitis and
PD were graded 03. LN assessment included maximum short axis, cortical hypertrophy (CH) and PD
signal distribution. All patients with active disease were re-evaluated prospectively 3 months after initiation
of therapy.
Results. PD-US signs of axillary LN remodelling were observed in 7 out of 10 patients with active disease
despite the absence of clinical lymphoadenopathy. Subclinical alterations were detected in both early
untreated RA and in established disease. Characteristic structural changes consisted of hypertrophy of
the LN cortex and PD signal amplification in cortical and hilar regions. Cervical LNs in active disease and
axillary LNs in clinical remission were unaffected. LN PD amplification returned to normal ranges in patients
with baseline alterations re-evaluated 3 months after therapy with TNF-a blocking agents and/or MTX.
Conclusion. Draining LNs in RA are subjected to subclinical intra-parenchymal changes and vascular flow
modulation detectable by PD-US. Sonographic signs of LN involvement associate with disease activity
and are reversible upon treatment. These data point at LN reactivity as a dynamic component of RA
inflammatory cascade and an attractive platform to be explored in prognostic and response to therapy
evaluations.
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Introduction
RA is a chronic inflammatory disease of unknown aeti-
ology. While the SM is the main target of the inflammatory
process, pathological alterations can be detected both
systemically [1] and juxta-articularly [2]. In this perspec-
tive, a relevant but still poorly investigated district is the
draining lymph node (LN), an anatomical structure poten-
tially involved in multiple pathological aspects of the dis-
ease such as the control of cell efflux from the joint and
the generation of local immunological responses [3].
Prompted by recent elegant studies in animal models,
this issue is now the object of growing attention. Changes
in LN drainage capacity have indeed been recognized in
TNF transgenic mice, showing a highly predictive value for
arthritis progression in the knee [4]. Draining LNs are
essential for early induction of autoantibodies in K/BxN
arthritic mice [5]. This process has been proved by loss
of function experiments to be dependent on LN follicular
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dendritic cells [6], a cell subset whose integrity is dis-
rupted by anti-TNF therapy in RA [7]. The possible applic-
ability of these findings to human pathology is supported
by the well-known occurrence of lymphadenopathy in the
course of the disease and by histological studies reporting
follicular hyperplasia, increased plasmacytosis and RF
deposition in peripheral LNs [8].
Despite these observations, the actual prevalence, the
patho-physiological role and the dynamics of draining LN
involvement in the course of human arthritis are still largely
unclear due to the ethical limitations in performing serial
assessments through biopsy and invasive imaging pro-
cedures. The introduction of non-invasive techniques
allowing LN structural analysis in large and unbiased co-
horts through serial assessments is, therefore, a key step
to allow translation of current knowledge from mice to
humans.
Power Doppler ultrasonography (PD-US) is an accurate
and sensitive tool for the characterization of superficial
LNs in humans, adopted in the pre-operative work-up of
cancers, and in follow-up studies aimed at assessing
the efficacy of chemotherapy or radiotherapy [9]. In this
study, we have explored the suitability of PD-US for the
assessment of axillary LN status in RA, evaluating the
existence of structural and dynamic modifications in
well-characterized stages of the disease.
Methods
Study population
Fifteen patients fulfilling the 1987 ACR revised criteria for
the classification of RA [10] were selected within three
disease categories according to stringent clinical param-
eters: (i) early untreated RA (DMARD and CS naı¨ve, dis-
ease duration <6 months, 44-joint DAS> 2.4). This group
included two females and three males with mean (S.D.) age
of 54.4 (17.7) years, disease duration of 4.4 (1.4) months
and DAS 3.64 (0.45). All patients were evaluated at base-
line and at 3 months after therapy with MTX 15 mg/week;
(ii) established, DMARD-refractory RA (disease duration
>12 months, candidate for anti-TNF therapy, DAS> 2.4).
This group included four females and one male with mean
(S.D.) age of 60.4 (6.1) years, disease duration of 110.4
(142.3) months and DAS 3.84 (0.49). All patients were
evaluated at baseline and at 3 months after additional
therapy with etanercept 50 mg/week; and (iii) established
RA in clinical remission [disease duration >12 months,
previous history of active disease (DAS> 2.4), DMARD-
induced stable remission (DAS< 1.6) in the previous
69 months]. This latter group included four females and
one male with mean (S.D.) age of 55 (16.6) years, disease
duration of 28.2 (10.5) months and DAS 1.09 (0.53). Five
healthy volunteers (four females and one male, aged
3568 years) were recruited as controls. Exclusion criteria:
(i) clinical history of neoplastic, autoimmune and chronic
infectious diseases; and (ii) vaccinations or acute infec-
tions in the 6 months before recruitment. Informed con-
sent was obtained in all cases according to the local
ethical committee guidelines. The study was approved
by IRCCS Policlinico San Matteo Foundation Ethics
Committee (code no. 08004598/b).
Joint and LN PD-US
Axillary and cervical LNs were examined by two inde-
pendent radiologists (S.A. and F.C.) with experience in
LN PD-US. A GE LogiqE9 (General Electric Medical
Systems) with a high-frequency linear-array transducer
(615 MHz) was used. The same operators blinded to clin-
ical data performed B mode and PD examinations assess-
ing the following structural parameters: LN maximum
short axis, the degree of cortical hypertrophy (CH), vas-
cular architecture and distribution by PD [9, 11]. Axillary
LN CH and PD were rated according to semi-quantitative
(CH) or qualitative (PD) three-point scores adapted from
previously published methods [9, 12]. For CH: 0 = thin
(hypoechoic cortex< 3 mm); 1 = hypertrophic (hypoechoic
cortex thicker than 3 mm); 2 = highly hypertrophic (hypoe-
choic cortex thicker than 6 mm) [12]; and for vascularity:
0 = no vessels or only hilar; 1 = hilar and cortical; 2 = pre-
dominantly subcapsular/cortical [9]. Exact agreement
between investigators with regard to the presence of CH
and PD alterations was found in 37 (92.5%) out of 40 and
36 (90%) out of 40 axillary stations analysed with weighted
k values of 0.793 and 0.813 for CH and PD scores, re-
spectively. Minor discrepancies were resolved by mutual
agreement. Synovitis was assessed using a GE LogiqE9
(General Electric Medical Systems) with a high-frequency
linear-array transducer (915 MHz) on MCP and wrist
joints as dorsal transversal and longitudinal scanning.
Each joint was assessed for grey scale (GS) and PD
signal with a semi-quantitative scale (03/joint, total
score: 018) as previously described [13].
Serum autoantibody measurement
Immunoglobulin (Ig)M RF and IgG anti-citrullinated
peptide autoantibodies (ACPAs) were determined by
nephelometry (Immage 800; Beckman Coulter) and a
second-generation fluorescence enzyme immunoassay
(Immunocap; Phadia), respectively, according to the
manufacturer’s recommendations.
Results
Ten patients with active disease underwent clinical exam-
ination and PD-US assessment of axillary-cervical LNs
and of ipsilateral wristMCP joints on the same day. At
recruitment, none but one of the patients showed clinically
detectable lymphadenopathy, despite evidence of arthritis
in all cases (mean swollen joints/arm: 4.1, range: 08;
mean tender joints/arm: 3.8, range: 09). US joint exam-
ination confirmed the presence of PD-positive signal in
nine patients (median PD score/arm: 1, range: 09) and
GS alterations in 10 out of 10 patients (median GS score/
arm: 3, range: 17).
Despite negative clinical examination, US could reveal
clear-cut changes in axillary LN structure in 7 out of
10 patients (5 out of 5 with established disease and
2 out of 5 with early RA). Blood flow alterations (score51)
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were detected in all seven patients, bilaterally in six out of
seven cases. Compared with controls, the most distin-
guishable trait was PD signal amplification in LN hilus
associated with its extension through the cortex, some-
times reaching the subcapsular rim (Fig. 1). Intra-
parenchymal changes were detected in six out of seven
patients, bilaterally in four cases and occurred as an
enlargement of the hypoechoic cortical region (score 1
in all cases) associated with LN short axis increase
(mean 0.8 vs 0.56 cm, in patients with normal cortex;
P= 0.03 by t-test) (Fig. 1). Despite cortical enlargement,
no signs of focal lobulation or other major morphological
abnormalities [12] were observed in our study population.
LN PD-US alterations were observed in both ACPA/RF
seropositive and seronegative disease. No significant dif-
ferences were observed in ACPA IgG or RF IgM titres in
patients with or without axillary LN modifications (data not
shown). Conversely, LN status appeared related to the
degree of arthritis in drained joints, as indicated by the
systematic detection of normal parameters in cervical
LNs during active disease and by the association between
axillary LN PD-US alterations and joint PD-US scores in
ipsilateral arms (Fig. 1).
In keeping with this concept, no signs of LN reactivity
were observed in five out of five patients with previous
history of active disease and in stable remission (Fig. 2),
who showed LN PD-US features comparable with nor-
mal controls. To confirm the plasticity of LN structural
changes, all patients with active disease were re-
evaluated after 3 months of therapy. Eight out of 10 pat-
ients showed good (n = 6) or moderate (n= 2) EULAR
response. Of note, despite persistence of LN cortical
widening at this time point, PD amplification reversal
was observed in six out of six patients with baseline axil-
lary LN alterations who showed clinical response (Fig. 2),
whereas no changes were observed in LNs featuring
score 0 at baseline. LN PD alterations persisted after
treatment in the only non-responder patient who had a
positive baseline PD signal.
Discussion
We show that LNs draining affected joints in RA are
subjected to intra-parenchymal structural changes and
vascular flow modulation, independently of clinically
FIG. 1 Ultrasonographic appearance of axillary LNs in RA. (A) Representative images of an LN with thin cortex (white #,
left panel) and rare PD signal (right panel). A PD-US image of a representative ipsilateral MCP joint is shown in (B).
(C) Representative images of an LN with hypertrophic cortex (white # in left panel) and PD signal amplification (right
panel). A PD-US image of an ipsilateral MCP joint is shown in (D). In (E), PD and GS total scores per arm (wrist and IV
MCP joints) are plotted according to the presence (LN+) or absence (LN) of LN alterations in ipsilateral axillae (n= 20).
The horizontal line represents the median. P-value was calculated by MannWhitney U-test.
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detectable lymphadenopathy. Subclinical LN involvement
associates with disease activity, is reversible upon treat-
ment and can be monitored by non-invasive techniques
such as PD-US.
It has been proposed that synovitis severity and LN
drainage are functionally inter-dependent in animal
models, pointing at the relevance of the jointLN complex
as a pathological unit [4]. Data presented herein corrob-
orate and extend these observations, demonstrating that
involvement of LNs draining hands and wrists (the primary
target of RA) can integrate joint pathology in humans both
in early and established disease. This concept is relevant
not only for its physio-pathological implications, but also
in light of recent response to treatment studies revealing
that pivotal modifications of the afferent lymphatic system
and secondary lymphoid organ function are induced by
effective biological agents such as anti-TNF, anti-CD20
and CTLA-4-Ig [4, 7, 1416].
In this perspective, an important finding of our work is
that PD-US signs of LN involvement in RA are not limited
to dimensional increase, but include intra-nodal modifica-
tions indicative of biological changes. It has been shown
that the hypoechoic cortex on sonograms relates to
the follicular and paracortical areas of human LNs, the
latter enriched in lymphatic sinuses and T cells [12]. The
observed hypertrophy of RA LN cortical region is thus
likely to be determined by specific expansion of these
compartments, a phenomenon that is inducible by experi-
mental immunization of normal mice [17] and that occurs
spontaneously in TNF transgenics and K/BxN strains
[4, 18]. LN reactivity in these systems associates with
amplification of local blood flow [18, 19], a process that
we could clearly detect by PD-US in RA.
Ultrasonographic signs of LN remodelling were de-
tected in both ACPA/RF seropositive and seronegative
RA. High ACPA/RF titres were maintained without
ongoing axillary LN reactivity, indicating that LN involve-
ment is not an intrinsic feature of the ACPA/RF+ disease
subset. Rather, our cross-sectional and prospective ana-
lyses point at LN involvement as a dynamic phenomenon,
FIG. 2 Ultrasonographic appearance of axillary LNs following treatment and in remission. Representative images of LN
PD-US in a patient with good EULAR response is shown in (A) (baseline) and (B) (3 months follow-up). Note the reversal of
PD alterations (B, middle panel) despite persistency of CH (B, upper panel). Graphs in (A) and (B) show the mean (dark
grey columns) and S.D. (error bars) of the DAS value at baseline (A) and at 3 months (B) in the eight patients with good/
moderate EULAR response. Reference scale: left side of the graphs. The light grey columns show the percentage of
axillary sites with LN CH and PD alterations out of 16 sites analysed. Reference scale: right side of the graphs. (C) A
representative PD-US image of an axillary LN from a patient in clinical remission with no PD or CH alterations. The graph
in (C) shows the mean DAS value and the percentage of axillary LN alterations in the five patients in remission.
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partly related to the degree of disease activity at drained
sites and reversible upon anti-inflammatory treatment. As
the effect of biologic therapies is not restricted to the
synovium [7, 15, 16] and clinical response cannot be en-
tirely predicted by synovial changes [20], it would there-
fore be relevant to investigate LN reactivity at earlier time
points in larger prospective studies to dissect the relation-
ship between LN and joint changes according to clinical
outcomes. Further studies are also warranted to charac-
terize the LN US picture in its histological and molecular
aspects, in order to ascertain whether US alterations are
determined by specific adaptive immunological responses
or by non-specific adaptations to inflammation.
In conclusion, despite the small number of patients stu-
died, our data suggest that the draining LN participates in
the pathological cascade of the disease and that assess-
ment of its structural changes can be explored for the
definition of dynamic and clinically significant biomarkers
in RA. Hypertrophy of the hypoechoic cortical region
and alterations of vascular flow can be monitored pro-
spectively through non-invasive, cost-effective imaging
approaches, indicating the feasibility of their serial assess-
ment in human research.
Rheumatology key messages
. PD-US identifies subclinical involvement of draining
LNs in RA.
. Typical LN changes recognized by PD-US include
CH and vascular flow amplification.
. PD-US signs of LN involvement associate with dis-
ease activity and are reversible upon treatment.
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